Wendy McKinnon
Women's Health · Longview, TXNPI 1790051548
Payments from drug & device makers
Across 21 payments — averaging $25.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shield Therapeutics Inc$104
- GSK$99
- Mayne Pharma Commercial LLC$83
- Hologic Sales And Service, LLC$55
- Johnson & Johnson$36
- Astellas Pharma US Inc$33
- plus $125 from 6 others
What the payments were for
- Food & beverage$535100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shield Therapeutics Inc | 2 | $104 |
| GSK | 1 | $99 |
| Mayne Pharma Commercial LLC | 4 | $83 |
| Hologic Sales And Service, LLC | 2 | $55 |
| Johnson & Johnson | 2 | $36 |
| Astellas Pharma US Inc | 2 | $33 |
| Avion Pharmaceuticals | 2 | $32 |
| Exeltis, USA Inc. | 2 | $31 |
| Agile Therapeutics, Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Evofem Biosciences, Inc. | 1 | $13 |
| Lupin Inc. | 1 | $13 |
How this compares
$535 in reported general payments places this provider in the 65th percentile of 609 women's health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 159 | $8,759 |
| Estradiol (Once Weekly)Estradiol | 44 | $2,203 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 25 | $532 |
| ProgesteroneProgesterone, Micronized | 22 | $454 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 23 | $233 |
| Norethindrone Acetate | 12 | $121 |
| Temazepam | 19 | $115 |
| Lorazepam | 12 | $114 |
| Fluconazole | 11 | $82 |
| Alprazolam | 17 | $79 |
| Metronidazole | 12 | $64 |
| Alendronate Sodium | 12 | $31 |
| Tri-Lo-EstaryllaNorgestimate-Ethinyl Estradiol | 12 | $20 |
Paid to pharmacies, not to this prescriber.
Other women's health in Longview
- Margaret DodsonLongview$6K
- Evelyn TingGrapevine$89K
- Christina TrumanWaco$70K
- Kayla CastanedaEl Paso$53K
- Shelagh LarsonFort Worth$43K
- Joyce MillerDallas$37K
- Deborah BrownBeaumont$36K
- Joyce MillerOdessa$36K
- Amanda ArmondAustin$17K
- Joann St PierreHouston$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.